A Phase 2b, Randomized, Controlled Trial Evaluating GS-5806 in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Presatovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 02 Oct 2017 Status changed from active, no longer recruiting to completed.
- 20 Jun 2017 The trial has been completed in Austria
- 28 Apr 2017 Planned End Date changed from 1 Apr 2017 to 1 Mar 2018.